Mam­moth Bio­sciences teams with GSK to put Covid-19 CRISPR tests at home, air­ports, bor­ders

The old CRISPR ri­val­ry is back in pan­dem­ic fash­ion.

Two weeks af­ter Feng Zhang-found­ed Sher­lock Bio­sciences launched the first Covid-19 CRISPR test, Jen­nifer Doud­na-found­ed Mam­moth Bio­sciences has part­nered with Glax­o­SmithK­line on their own tests, with plans to even­tu­al­ly roll it out in places like homes and air­ports. Take a swab, get a green light, and you’re good to board.

“You can al­so imag­ine about build­ing a com­pan­ion app, so you’re con­nect­ing to next steps or tele­health” if you test pos­i­tive, Mam­moth CEO and co-founder Trevor Mar­tin told End­points News. “There’s a lot of op­por­tu­ni­ty to re­al­ly in­te­grate in­to the broad­er ecosys­tem. That’s why we’re work­ing with an or­ga­ni­za­tion like GSK — they ob­vi­ous­ly have a glob­al reach to un­der­stand dif­fer­ent needs, how to scale, and are plugged in­to this broad­er ecosys­tem.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER